Salvador Payán Pernía: Arguing against a Significant Role for Erythropoietin Analogues in the Management of PRCA
Salvador Payán Pernía, Member of the Board of Directors of the Erythropathology Group at Spanish Society of Hematology and Hemotherapy (SEHH), shared on LinkedIn about a recent article he and his co-authord, published in Blood Advances, adding:
“I’m delighted to have contributed to this European multicentre study on acquired pure red cell aplasia (PRCA), one of the rare diseases I most enjoy managing.
Acquired PRCA is an underrecognized entity, even among hematologists, as reflected by the median time from presentation to treatment of 2 months (range: 1–204 months) observed in our study.
PRCA should be promptly suspected in any patient with severe anemia and a low reticulocyte count. In our study, earlier initiation of cyclosporine A was associated with a better response.
Our study also shows that PRCA is characterized by markedly elevated erythropoietin levels (median: 908 mIU/mL; range: 29–3000 mIU/mL), likely related to reduced degradation by erythroblasts.
These findings argue against a significant role for erythropoietin analogues in the management of PRCA.
At diagnosis, most patients had elevated ferritin levels and transferrin saturation, reflecting rapid iron accumulation and reduced iron utilization.
Reticulocytes are crucial not only for diagnosis but also as an early marker of response, as highlighted in the paper –look at the reticulocytes!
Thanks to Bruno Fattizzo and Francesco Versino for their initiative, leadership, and excellent work.”
Title: Clinical Heterogeneity and Outcome of acquired PRCA: a Multicenter European Study
Authors: Francesco Versino,Marc Michel,Jennifer Vidler, Salvador Payán-Pernía,Roochi Trikha,Shreyans A Gandhi,Sukanya Gogoi,Manujasr, Wimalachandra,Omar Racchi,Maria Teresa Lupo-Stanghellini,Sabrina Giammarco,Maria Arguello Marina,Mara Memoli,Andreas Glenthøj,Gabriele Merati, Yamuna Wasanthi Wickramasinghe,Aparna Chitharanjan,Mylene Hemmer,Mariasanta Napolitano,Margarita Jimenez-Jambrina,Filippo Brioschi, Antonio Palma-Vallelano,Tomas Jose Gonzalez-Lopez,Cristina Clissa,Marta Bortolotti,Giacinto Luca Pedone,Giorgio Alberto Croci,Francesco Passamonti, Wilma Barcellini, Austin G Kulasekararaj, Bruno Fattizzo
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 20, 2026, 01:43Oliver Weingärtner: Deprescribing of Lipid Lowering Drug after MI is Associated with Cardiovascular Events
-
Oct 19, 2026, 19:44Where You Live Should not Determine Whether You Receive Care – World Federation of Hemophilia
-
Oct 19, 2026, 19:42Belen Bianco: Prevention, Early Suspicion and an Interdisciplinary Approach Save Lives
-
Oct 19, 2026, 19:40Christina Chrysohoou: Catheter-Based LAAC vs OAC for Stroke Prevention in Atrial Fibrillation
-
Oct 19, 2026, 19:38Matthew Flick: A Two-Day Research Meeting on Fibrinogen, Hemostasis and Thrombosis
-
Oct 19, 2026, 19:37Hayat Saeed: Excited to Share Our Publication on the FGL1–Hepcidin Axis in Iron Homeostasis and Disease
-
Oct 19, 2026, 19:08IPAW 2026 Comes to a Close, but the Work Continues – PPTA
-
Oct 19, 2026, 17:44Paul Riley: Moderating a Webinar on Anticoagulation Monitoring
-
Oct 19, 2026, 16:36Christopher Pittman: Blood Clot Prevention Cannot End at Hospital Discharge